Nasdaq lpcn.

22 Sep, 2022, 16:10 ET. SALT LAKE CITY, Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment ...SALT LAKE CITY, May 8, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019, and provided a corporate update. First Quarter and Recent Corporate Highlights. Announced findings from the Ambulatory Blood Pressure Monitoring clinical …SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial ...27 Jan, 2022, 08:00 ET. SALT LAKE CITY, Jan. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...

Fiscal Q3 2023 ended 9/30/23. Get the latest Lipocine Inc (LPCN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and ...

Nov 8, 2023 · Quarter Ended September 30, 2023 Financial Results. Lipocine reported a net loss of $6.7 million, or ($1.27) per diluted share, for the three months ended September 30, 2023, compared with a net ... 31 Aug 2020 ... (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the US Food ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ...SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will ...Lipocine Inc. 01 Nov, 2023, 08:00 ET. "Late Breaking" abstract scheduled for oral presentation on November 13. SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a ...SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for "Compositions and Methods for Treating Central Nervous System …

SALT LAKE CITY, April 17, 2020 /PRNewswire/ -- Lipocine Inc.. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States Food and Drug Administration ("FDA") denied the Citizen Petition filed by Clarus Therapeutics Inc. ("Clarus") on October 2, …

Dec 1, 2023 · Financial Performance. In 2022, Lipocine's revenue was $500,000, a decrease of -96.90% compared to the previous year's $16.14 million. Losses were -$10.76 million, 1595.9% more than in 2021. Financial Statements.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers …SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The …Lipocine Inc. Common Stock (LPCN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.SALT LAKE CITY, Aug. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of concept LiFT ("Liver Fat intervention with oral Testosterone") clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH.By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2021 Financial and Operational Results On March 9, 2022 Lipocine (NASDAQ:LPCN) filed its Form 10-K and posted its earnings ...SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical ...SALT LAKE CITY, March 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced financial ...

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended ...Lipocine Inc. Common Stock (LPCN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis. Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating... Nov 9, 2022.Lipocine Inc (US:LPCN) has 0 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Lipocine Inc (NASDAQ:LPCN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.Lipocine Inc share price live 2.7700, this page displays NASDAQ LPCN stock exchange data. View the LPCN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lipocine Inc real time stock price chart below. You can find more details ...0.31%. $40.52B. LPCN | Complete Lipocine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

See the latest Lipocine Inc stock price (LPCN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.SALT LAKE CITY, Nov. 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from ...

19 Sep, 2023, 16:05 ET. SALT LAKE CITY, Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today ...SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...Lipocine (Nasdaq:LPCN) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Lipocine NasdaqCM:LPCN Stock …SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papapetropoulos, M.D. Ph.D., …By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD). The underlying drug in LPCN 1154 is brexanolone, which is approved in an intravenous (IV) formulation for PPD.Shares of NASDAQ:LPCN opened at $2.73 on Tuesday. The stock has a market capitalization of $14.52 million, a P/E ratio of -0.87 and a beta of 1.04. The stock’s …Virios Therapeutics (NASDAQ:VIRI) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and …Find real-time LPCN - Lipocine Inc stock quotes, company profile, news and forecasts from CNN Business./PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will...

SALT LAKE CITY, Aug. 7, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial ...

Upcoming Catalysts: LPCN 1144 Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH) Phase 2 Mid-2021 Phase 2 top-line change in liver fat data met primary endpo. LPCN Entering at Support …

With its stock down 8.2% over the past week, it is easy to disregard Lipocine (NASDAQ:LPCN). But if you pay close attention, you might find that its key financial indicators look quite decent ...SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract ...Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023. SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Lipocine Inc. …Nov 13, 2023 · SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ... SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will be held virtually. Presentation details are …Mar 11, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2021 Financial and Operational Results On March 9, 2022 Lipocine (NASDAQ:LPCN) filed its Form 10-K and posted its earnings ... SALT LAKE CITY, July 30, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh ...Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with ...Lipocine Inc. Common Stock (LPCN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Dec 5, 2023 · Lipocine Stock Up 3.8 %. Shares of NASDAQ LPCN opened at $2.73 on Tuesday. The firm has a market cap of $14.52 million, a PE ratio of -0.87 and a beta of 1.04. Lipocine has a 12-month low of $2.31 and a 12-month high of $10.33. The company’s fifty day simple moving average is $2.64 and its 200 day simple moving average is $3.81. Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Lipocine Inc. Common Stock (LPCN) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.Lipocine Inc. Common Stock (LPCN) · Cotizaciones · NOTICIAS Y ANÁLISIS.Instagram:https://instagram. australian stock brokersjpie etfcommercial real estate fundsmoon etf 28 Sep, 2021, 08:00 ET. SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...We feel now is a pretty good time to analyse Lipocine Inc.'s (NASDAQ:LPCN) business as it appears the company may be on the cusp of a considerable accomplishment. Lipocine Inc., a clinical-stage ... best international forex brokerssunpower. SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the European Association for the Study of the Liver ("EASL"), … does home insurance cover ceiling leaks LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate, with ...Nov 14, 2023 · Lipocine has generated ($3.14) earnings per share over the last year ( ($3.14) diluted earnings per share). Earnings for Lipocine are expected to grow in the coming year, from ($2.19) to ($1.47) per share. Lipocine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 8th, 2024 ...